The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).

Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep (2013) 1.43

Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms. Cent European J Urol (2015) 0.94

Tobacco exposure by various modes may alter proinflammatory (IL-12) and anti-inflammatory (IL-10) levels and affects the survival of prostate carcinoma patients: an explorative study in North Indian population. Biomed Res Int (2014) 0.93

Association of a Missense ALDH2 Single Nucleotide Polymorphism (Glu504Lys) With Benign Prostate Hyperplasia in a Korean Population. Int Neurourol J (2013) 0.84

DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol (2015) 0.83

Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)? BJU Int (2013) 0.81

Increased risk of benign prostate hyperplasia in sleep apnea patients: a nationwide population-based study. PLoS One (2014) 0.81

Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol (2016) 0.80

Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm (2014) 0.80

Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis. Am J Pathol (2014) 0.79

Preoperative risk factors of postoperative delirium after transurethral prostatectomy for benign prostatic hyperplasia. Int J Clin Exp Med (2015) 0.79

Effects of hexanic extract of serenoa repens (permixon(®) 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate (2015) 0.79

Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy. Curr Urol (2016) 0.78

Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. Endocrinology (2015) 0.78

Elevated red blood cell distribution width in benign prostatic hyperplasia patients with metabolic syndrome. Int J Clin Exp Med (2015) 0.78

Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Med Sci Monit (2015) 0.77

Association between single nucleotide polymorphism of vitamin D receptor gene FokI polymorphism and clinical progress of benign prostatic hyperplasia. ScientificWorldJournal (2015) 0.76

Survivin and NAIP in Human Benign Prostatic Hyperplasia: Protective Role of the Association of Serenoa repens, Lycopene and Selenium from the Randomized Clinical Study. Int J Mol Sci (2017) 0.75

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. J Inflamm (Lond) (2016) 0.75

Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells. Proc Natl Acad Sci U S A (2017) 0.75

Therapeutic efficacy of Cernilton in benign prostatic hyperplasia patients with histological prostatitis after transurethral resection of the prostate. Int J Clin Exp Med (2015) 0.75

Prostate calculi can higher urinary retention probability and worsen uncomfortable feeling after prostate biopsy but not predict cancer. Int J Clin Exp Med (2015) 0.75

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLoS One (2015) 0.75

The role of the prostate in male fertility, health and disease. Nat Rev Urol (2016) 0.75

CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway. Sci Rep (2017) 0.75

Lower urinary tract symptoms among Caucasian-European men who have sex with men: findings from a real-life survey. Prostate Cancer Prostatic Dis (2015) 0.75

Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men. Asian J Androl (2015) 0.75

D-002 (beeswax alcohols): concurrent joint health benefits and gastroprotection. Indian J Pharm Sci (2015) 0.75

Clinical Significance of Periurethral Calcification According to the Location in Men With Lower Urinary Tract Symptoms and a Small Prostate Volume. Int Neurourol J (2017) 0.75

Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. Ci Ji Yi Xue Za Zhi (2017) 0.75

Relation between histological prostatitis and lower urinary tract symptoms and erectile function. Prostate Int (2017) 0.75

Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78

Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58

A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol (2012) 4.08

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol (2010) 3.95

Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93

Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol (2008) 3.64

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol (2010) 3.55

Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol (2012) 3.53

Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol (2009) 3.39

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol (2009) 3.31

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26

Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol (2003) 3.23

Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18

A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol (2011) 3.18

Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol (2012) 3.17

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14

Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10

Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol (2011) 3.07

The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06

Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol (2011) 3.03

Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97

Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J (2006) 2.91

Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84

Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol (2010) 2.82

Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol (2010) 2.82

Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol (2012) 2.77

Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology (2011) 2.76

Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76

Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol (2011) 2.74

A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur Urol (2007) 2.68

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol (2008) 2.65

Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol (2011) 2.62

Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55

Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. Int J Radiat Oncol Biol Phys (2011) 2.55

Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55

A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol (2013) 2.52

Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol (2013) 2.48

A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol (2009) 2.47

Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol (2012) 2.46

Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol (2012) 2.45

The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43

Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43

Varicocele and male factor infertility treatment: a new meta-analysis and review of the role of varicocele repair. Eur Urol (2011) 2.41

Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41

EAU guidelines on penile curvature. Eur Urol (2012) 2.40

Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol (2010) 2.38

Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol (2006) 2.37

Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33

Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31

Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30

A prospective, non-randomized trial comparing robot-assisted laparoscopic and retropubic radical prostatectomy in one European institution. BJU Int (2009) 2.30

Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30

The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis (2012) 2.29

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29

Laparoendoscopic single-site and natural orifice transluminal endoscopic surgery in urology: a critical analysis of the literature. Eur Urol (2010) 2.28

BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol (2005) 2.26

Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial. Eur Urol (2007) 2.24

Long-term results of small intestinal submucosa graft in bulbar urethral reconstruction. Urology (2012) 2.21

Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. Eur Urol (2011) 2.20

Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. Urology (2011) 2.20

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20

Bulbar urethroplasty using buccal mucosa grafts placed on the ventral, dorsal or lateral surface of the urethra: are results affected by the surgical technique? J Urol (2005) 2.19

Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18

Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17

Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol (2012) 2.17

Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol (2003) 2.17

Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol (2007) 2.16

Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution. Urology (2010) 2.15

Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. Eur Urol (2008) 2.15

A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol (2010) 2.13

Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry (2006) 2.13